James B. Aggen

1.7k total citations
22 papers, 1.1k citations indexed

About

James B. Aggen is a scholar working on Molecular Biology, Organic Chemistry and Molecular Medicine. According to data from OpenAlex, James B. Aggen has authored 22 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 6 papers in Organic Chemistry and 6 papers in Molecular Medicine. Recurrent topics in James B. Aggen's work include Antibiotic Resistance in Bacteria (6 papers), Marine Toxins and Detection Methods (4 papers) and Chemical synthesis and alkaloids (4 papers). James B. Aggen is often cited by papers focused on Antibiotic Resistance in Bacteria (6 papers), Marine Toxins and Detection Methods (4 papers) and Chemical synthesis and alkaloids (4 papers). James B. Aggen collaborates with scholars based in United States, Canada and Germany. James B. Aggen's co-authors include A. Richard Chamberlin, Angus C. Nairn, Richard Chamberlin, John M. Humphrey, Eliana S. Armstrong, N. R. Towers, W Fischer, Daniel R. Dietrich, Christopher O. Miles and Ian Garthwaite and has published in prestigious journals such as Journal of the American Chemical Society, Environmental Science & Technology and Cancer Research.

In The Last Decade

James B. Aggen

21 papers receiving 1.0k citations

Peers

Countries citing papers authored by James B. Aggen

Since Specialization

Citations

This map shows the geographic impact of James B. Aggen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James B. Aggen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James B. Aggen more than expected).

Fields of papers citing papers by James B. Aggen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James B. Aggen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James B. Aggen. The network helps show where James B. Aggen may publish in the future.

Co-authorship network of co-authors of James B. Aggen

This figure shows the co-authorship network connecting the top 25 collaborators of James B. Aggen. A scholar is included among the top collaborators of James B. Aggen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James B. Aggen. James B. Aggen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract B108: 4EBP3 mRNA as a biomarker of therapeutic response to treatment with mTORC1 inhibitors 2019 ·Molecular Cancer Therapeutics ·Bianca J. Lee, Nuntana Dinglasan, (unknown), (unknown), (unknown), G. Leslie Burnett, James B. Aggen, Robert J. Nichols, Mallika Singh, David Wildes, (unknown)	0
2	DDIS-33. SELECTIVE AND COMPLETE INHIBITION OF mTORC1 BY BI-STERIC mTOR INHIBITORS DRIVES THERAPEUTIC RESPONSE IN GLIOBLASTOMA 2019 ·Neuro-Oncology ·Qi Fan, Edward Lorenzana, (unknown), (unknown), Ozlem Aksoy, Zhenyi An, Tomoko Ozawa, (unknown), Kevan M. Shokat, James B. Aggen, (unknown), Mallika Singh, Nicholas Butowski, David R. Raleigh, William A. Weiss	1
3	Compound design guidelines for evading the efflux and permeation barriers of Escherichia coli with the oxazolidinone class of antibacterials: Test case for a general approach to improving whole cell Gram-negative activity 2017 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Khuloud Takrouri, (unknown), (unknown), (unknown), Paola Zucchi, (unknown), (unknown), Penny J. Beuning, Elizabeth B. Hirsch, James B. Aggen	12
4	Synthesis and Microbiological Evaluation of Novel Tetracyclic Fluoroquinolones 2017 ·ChemMedChem ·Allan S. Wagman, Ryan T. Cirz, Glenn McEnroe, James B. Aggen, Martin S. Linsell, (unknown), Sara López, Marcela Gómez, (unknown), (unknown), Thomas R. Belliotti, Christina R. Harris, (unknown), (unknown), R.D. Gaston, Heinz E. Moser	20
5	Progress against Escherichia coli with the Oxazolidinone Class of Antibacterials: Test Case for a General Approach To Improving Whole-Cell Gram-Negative Activity 2016 ·ACS Infectious Diseases ·Khuloud Takrouri, (unknown), (unknown), Paola Zucchi, (unknown), (unknown), (unknown), Penny J. Beuning, Elizabeth B. Hirsch, James B. Aggen	25
6	Multivalent design of long-acting β2-adrenoceptor agonists incorporating biarylamines 2014 ·Bioorganic & Medicinal Chemistry Letters ·John R. Jacobsen, James B. Aggen, (unknown), Uwe Klein, Juergen Pfeiffer, (unknown), Glyn Thomas, (unknown), Edmund J. Moran	7
7	Toxicity Modulation, Resistance Enzyme Evasion, and A-Site X-ray Structure of Broad-Spectrum Antibacterial Neomycin Analogs 2014 ·ACS Chemical Biology ·Juan Pablo Maianti, Hiroki Kanazawa, Paola Dozzo, (unknown), (unknown), Eliana S. Armstrong, Darin J. Hildebrandt, Timothy R. Kane, Micah J. Gliedt, (unknown), Martin S. Linsell, James B. Aggen, Jiro Kondo, Stephen Hanessian	22
8	1-(4-Phenylpiperazin-1-yl)-2-(1H-pyrazol-1-yl)ethanones as novel CCR1 antagonists 2013 ·Bioorganic & Medicinal Chemistry Letters ·Andrew M. K. Pennell, James B. Aggen, Subhabrata Sen, Wei Chen, (unknown), (unknown), Lianfa Li, Kevin L. Greenman, Trevor T. Charvat, (unknown), Daniel J. Dairaghi, John Joseph Wright, Penglie Zhang	11
9	Toward Overcoming Staphylococcus aureus Aminoglycoside Resistance Mechanisms with a Functionally Designed Neomycin Analogue 2011 ·ACS Medicinal Chemistry Letters ·Stephen Hanessian, Alexandre Giguère, (unknown), Juan Pablo Maianti, (unknown), James B. Aggen, Martin S. Linsell, (unknown), Darin J. Hildebrandt, Timothy R. Kane, Paola Dozzo, Micah J. Gliedt, (unknown), (unknown), Eliana S. Armstrong	18
10	In Vivo Efficacy of the Novel Aminoglycoside ACHN-490 in Murine Infection Models 2011 ·Antimicrobial Agents and Chemotherapy ·Noe Reyes, James B. Aggen, Corwin F. Kostrub	33
11	Synthesis and Spectrum of the Neoglycoside ACHN-490 2010 ·Antimicrobial Agents and Chemotherapy ·James B. Aggen, Eliana S. Armstrong, (unknown), Paola Dozzo, Martin S. Linsell, Micah J. Gliedt, Darin J. Hildebrandt, (unknown), (unknown), (unknown), Sara López, Marcela Gómez, Kenneth B. Wlasichuk, (unknown), George H. Miller, Heinz E. Moser	206
12	ACHN-490, a Neoglycoside with Potent In Vitro Activity against Multidrug-Resistant Klebsiella pneumoniae Isolates 2009 ·Antimicrobial Agents and Chemotherapy ·Andrea Endimiani, Kristine M. Hujer, Andrea M. Hujer, Eliana S. Armstrong, (unknown), James B. Aggen, Robert A. Bonomo	98
13	Exploring the Positional Attachment of Glycopeptide/β-lactam Heterodimers 2008 ·The Journal of Antibiotics ·Daniel D. Long, James B. Aggen, Jason Chinn, Seok Ki Choi, B. G. CHRISTENSEN, (unknown), David W. Green, Sharath S. Hegde, J. Kevin Judice, Koné Kaniga, Kevin M. Krause, Michael R. Leadbetter, Martin S. Linsell, Daniel G. Marquess, Edmund J. Moran, Matthew B. Nodwell, John Pace, Sean Trapp, (unknown)	36
14	A Multivalent Approach to Drug Discovery for Novel Antibiotics 2008 ·The Journal of Antibiotics ·Daniel D. Long, James B. Aggen, B. G. CHRISTENSEN, J. Kevin Judice, Sharath S. Hegde, Koné Kaniga, Kevin M. Krause, Martin S. Linsell, Edmund J. Moran, John Pace	35
15	Linearized and truncated microcystin analogues as inhibitors of protein phosphatases 1 and 2A 2003 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), James B. Aggen, A. Richard Chamberlin	23
16	Microcystin analogues comprised only of adda and a single additional amino acid retain moderate activity as PP1/PP2A inhibitors 2003 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), James B. Aggen, (unknown), (unknown), A. Richard Chamberlin	41
17	Regulation of protein phosphatase-1 2000 ·Chemistry & Biology ·James B. Aggen, Angus C. Nairn, Richard Chamberlin	152
18	The design, synthesis, and biological evaluation of analogues of the serine-threonine protein phosphatase 1 and 2A selective inhibitor microcystin LA: rational modifications imparting PP1 selectivity 1999 ·Bioorganic & Medicinal Chemistry ·James B. Aggen, John M. Humphrey, Carla‐Maria Gauss, Hsien‐Bin Huang, Angus C. Nairn, A. Richard Chamberlin	38
19	ChemInform Abstract: Total Synthesis of the Serine‐Threonine Phosphatase Inhibitor Microcystin‐LA. 1997 ·ChemInform ·John M. Humphrey, James B. Aggen, A. Richard Chamberlin	3
20	Total Synthesis of the Serine-Threonine Phosphatase Inhibitor Microcystin-LA 1996 ·Journal of the American Chemical Society ·John M. Humphrey, James B. Aggen, A. Richard Chamberlin	75

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact